Aker BioMarine

Earnings Release • Nov 1, 2022

Aker BioMarine ASA - results third quarter 2022

Aker BioMarine ASA - results third quarter 2022

1 November 2022: Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 68 million and Adjusted EBITDA of USD 19 million for the third quarter 2022.

“Aker BioMarine delivers higher sales growth and EBITDA, driven by improvement in all segments compared to the same quarter last year. Especially the Qrill segment reports strong figures, with high sales volumes and prices for Qrill Aqua. We have significantly improved our Antarctic krill harvesting, and so far this year, the production of krill meal is above 50,000 tons, which is 23% above last year.”, said Matts Johansen, CEO of Aker BioMarine.

Highlights third quarter:

- Revenues of USD 68 million, up 10% from same quarter last year

- Adjusted EBITDA of USD 19 million, up from USD 15 million the same quarter last year

- Sales in the Ingredients segment, up 11% from same quarter last year

- Sales in the Brands segment, up 10% from same quarter last year

- Offshore production volume was 12,737 MT in the quarter, 77% above same quarter last year

For 2022, Aker BioMarine targets revenue growth of 8%-12%, with an adj. EBITDA margin of 23-26%. The company expects a lower revenue growth and at the same time higher margins than previously targeted, which implies an unchanged targeted adj. EBITDA.

At 09:00 CET today, the management hosts a webcast. Following the presentation, there will be a Q&A session, where written questions can be submitted to ir@akerbiomarine.com.

The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor.

A replay of the presentation and Q&A session material will be made available soon after the presentation at the same web address.

For further information, please contact

Carl Christian Bachke, Investor Relations

Mobile: +47 909 808 48

Email: carl.bachke@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

About Aker BioMarine

Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.